Lenovo Unveils Next-Gen GOAST v4.0 to Speed up Genome Sequencing

The new version can cut the speed of genome sequencing to just 24 minutes per genome sequence

Lenovo has announced the launch of Genomics Optimisation and Scalability Tool (GOAST) v4.0, the latest version of its high-performance genomics computing solution.

The new version can cut the speed of genome sequencing to just 24 minutes per genome sequence.

As per reports, a single node is capable of managing roughly 22,000 genomes each year, nearly three times the throughput of earlier versions, which could accelerate breakthroughs in precision medicine, drug discovery, and agricultural genomics.

Key Highlights:

Genome sequencing, which traditionally takes 68 to 150 hours, is now expected to be completed in under 30 minutes with Lenovo’s GOAST v4.0.

It processes up to 22,000 genomes per node annually, enabling population-scale genomics projects.

The new version leverages optimized CPUs that deliver GPU-level performance at a lower cost, which can accelerate genomic analysis.

The technique also leverages AI-Driven Workflows, which can reduce manual intervention and streamline bioinformatics pipelines.

Further, GOAST v4.0 is available through Lenovo’s TruScale High-Performance Computing-as-a-Service (HPCaaS) model, offering pay-as-you-go access to laboratories, hospitals, and public health agencies for advanced genomics capabilities without the need for large-scale infrastructure investments.

Speaking about the new launch, Sumir Bhatia, President of Lenovo ISG Asia Pacific, said, “GOAST v4.0 breaks bioinformatics bottlenecks by combining Lenovo’s HPC expertise with cutting-edge genomics innovation.” “With this leap in performance and efficiency, we are enabling real-time discoveries that can save lives and advance global health equity,” he added.

First introduced in 2020, Lenovo’s GOAST is already deployed at leading research and healthcare institutions worldwide, including CSIR-IGIB and University of Delhi (India), BRIN (Indonesia), Novo Genomics (Saudi Arabia), and the Biobank of Thailand.

In Australia, a major children’s hospital is using GOAST to expand genomics research, while pharma companies in the Philippines and India are leveraging it to advance cancer research, accelerate drug discovery, and develop better treatment.

The v4.0 release integrates optimized algorithms, enhanced parallel processing, and AI-driven workflows, delivering unprecedented scalability for large-scale genomic projects.

As part of its “Smarter AI for All” initiative, the company said, GOAST v4.0 integrates high-performance computing with AI to make genomics research more cost-efficient and globally accessible.

The company anticipates increasing adoption across national health programs, research institutes, and pharmaceutical companies throughout the Asia Pacific and beyond.

Stay tuned for more such updates on Digital Health News